Proceedings of the National Academy of Sciences · 1999 · 248 citations · 28 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyChemotherapyStructure-activity RelationshipsCytotoxic ChemotherapyEnzyme InhibitionMicrotubule-associated ProteinsMicrotubule-targeting AgentsMitotic InhibitorsOncology PharmacologyBinding Affinity To TubulinCommon-feature Pharmacophore GenerationDrug Binding Sites On TubulinMicrotubule DestabilizersMicrotubule StabilizersNatural Product Microtubule InhibitorsTubulin Binding InhibitionTubulin Binding Sites
Taxol (paclitaxel), a complex diterpene obtained from the Pacific yew, Taxus brevifolia, is arguably the most important new drug in cancer chemotherapy. The mechanism of cytotoxic action for paclitaxel-i.e., the stabilization of microtubules leading to mitotic arrest-is now shared by four recently identified natural products, eleutherobin, epothilones A and B, and discodermolide. Their ability to competitively inhibit [3H]paclitaxel binding to microtubules strongly suggests the existence of a common binding site. Recently, we have developed nonaromatic analogues of paclitaxel that maintain high cytotoxicity and tubulin binding (e.g., nonataxel). We now propose a common pharmacophore that unites paclitaxel, nonataxel, the epothilones, eleutherobin, and discodermolide, and rationalizes the extensive structure-activity relationship data pertinent to these compounds. Insights from the common pharmacophore have enabled the development of a hybrid construct with demonstrated cytotoxic and tubulin-binding activity.
28
Promotion of microtubule assembly in vitro by taxol
Peter B. Schiff, Jane Fant, Susan Band Horwitz · Nature · 1979 · 3.6K citations
Structure of the αβ tubulin dimer by electron crystallography
Eva Nogales, Sharon G. Wolf, Kenneth H. Downing · Nature · 1998 · 2.1K citations